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and was well tolerated
in advanced myelofi-
brosis patients, includ-





nib 200 mg twice per
day in a pivotal ran-
domized phase 3 trial.
PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in
patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib.
Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or
200mg twice per day. Enhanced eligibility criteria, monitoring, and dosemodifications were
implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on
$35% spleen volume response (SVR) and$50% reduction in the 7-component total symptom
score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become
resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count
,503 103/mL) was present in 44%. SVR rates were highest with 200 mg twice per day (100
mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly
among patients with baseline platelet counts ,503 103/mL (17%; 4 of 24). Although TSS
response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day,
7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-
response relationship (–3%, 216%, and 227%, respectively). Pharmacokinetic and
pharmacodynamic modeling based on all available data showed greatest SVR and TSS
reduction at 200 mg twice per day compared with lower doses. Common adverse events
were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade
$3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day
demonstrated clinical activity and an acceptable safety profile and was selected as the
recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe
thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734.
Submitted 31 August 2020; accepted 14 October 2020; published online 24
November 2020. DOI 10.1182/bloodadvances.2020003314.
Send data sharing requests via e-mail to the corresponding author, Aaron T. Gerds, at
gerdsa@ccf.org.
The full-text version of this article contains a data supplement.
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Pacritinib is a novel inhibitor of JAK2, interleukin-1 receptor-
associated kinase 1 (IRAK1), FLT3, and CSF-1R that has
demonstrated clinical benefit in patients with myelofibrosis com-
pared with best available therapy in PERSIST-1 and PERSIST-2
phase 3 studies.1,2 Unlike the JAK inhibitors that are currently
approved in the United States for myelofibrosis (ruxolitinib and
fedratinib), pacritinib has been studied in patients presenting with
severe thrombocytopenia (platelet counts ,503 103/mL). In the
PERSIST studies, pacritinib was associated with clinically meaning-
ful spleen volume responses (SVRs) and improvements in disease-
associated symptoms in a substantial proportion of patients,
including those with severe baseline thrombocytopenia and those
who had previously received ruxolitinib. Severe thrombocytopenia
and failure of initial treatment represent poor prognostic factors for
patients with myelofibrosis. Severe thrombocytopenia is associated
with advanced disease, a higher risk of bleeding, increased risk of
leukemic transformation,3 and a shorter overall survival (median of
;15 months).4-6 After discontinuation of first-line ruxolitinib therapy,
median survival is only 13 to 14 months, and it is ;8 months for
patients with platelet counts ,1003 103/mL.7-9
The PERSIST studies indicate that pacritinib may address
a significant unmet need in patients with severe thrombocytopenia,
including those who are intolerant of or resistant to ruxolitinib.
Concerns over high-grade cardiac and bleeding events in these
studies, however, prompted development of the PAC203 phase 2
study, which was designed to identify the recommended pacritinib
dosage and to establish risk minimization measures, such as
exclusion criteria for patients with preexisting bleeding episodes or
cardiac disease, increased cardiac monitoring, and detailed dose
modification guidelines. Here, we present the results of the phase 2
PAC203 randomized dose-finding study in patients with advanced
myelofibrosis who were intolerant of or had become resistant to
ruxolitinib.
Methods
Study design and objective
The phase 2 PAC203 study was an open-label, randomized, dose-
finding study of pacritinib in patients with myelofibrosis previously
treated with ruxolitinib. The primary objective was to determine the
recommended dose of pacritinib. Secondary objectives were to
examine the dose-response relationship for efficacy and safety and
to further characterize pharmacokinetics (PK) and pharmacody-
namics (PD) of pacritinib. The selection of a recommended dose
was to be based on PAC203 efficacy and safety data through week
24 as well as dose- and exposure-response analyses using all
available data for pacritinib-treated patients from PAC203 and
previous studies. The study was conducted at 62 sites (supple-
mental Methods). The study was approved by the institutional
review boards at each institution and conducted in accordance with
the principles outlined in the Declaration of Helsinki.
Patients
Adult patients with primary or secondary myelofibrosis were eligible
if they had intermediate-1, intermediate-2, or high-risk disease
according to the Dynamic International Prognostic Scoring
System10 and were intolerant of ruxolitinib, which was defined as
treatment for 28 days or more, with treatment complicated by
a requirement for red blood cell (RBC) transfusion, grade $3
anemia, thrombocytopenia, hematoma, and/or hemorrhage while
being treated with a dosage of ,20 mg twice per day or were
resistant to ruxolitinib. Ruxolitinib failure was defined as treatment
for 3 or more months with,10% SVR or,30% decrease in spleen
length or regrowth to these parameters. Additional eligibility criteria
included splenomegaly $5 cm below the left costal margin, total
symptom score (TSS) $10 on the Myeloproliferative Neoplasm
Symptom Assessment Form Total Symptom Score (MPN-SAF TSS
2.0, 7-component version11) or single symptom score $5 or 2
scores$3, including only the symptoms of left upper quadrant pain,
bone pain, itching, or night sweats; Eastern Cooperative Oncology
Group performance status of 0 to 2; peripheral blast count ,10%;
absolute neutrophil count .0.5 3 109/L; adequate liver, renal, and
coagulation parameters; left ventricular ejection fraction $45%;
and life expectancy $6 months. Patients with grade $2 bleeding
events within the previous 3 months and those treated with
anticoagulation or antiplatelet agents (except for aspirin at dosages
#100 mg per day) within the past 14 days were excluded. Patients
with New York Heart Association Class $2 heart failure, grade $2
cardiac conditions within the previous 6 months, QTc prolongation
.450 msec during screening, and those treated with agents that
prolong the QT interval within the past 14 days were excluded.
Additional eligibility criteria are described in supplemental Methods.
All patients provided written informed consent.
Randomization and treatment
Patients were randomized 1:1:1 using an interactive Web response
system to receive pacritinib at 1 of 3 doses: 100 mg once per day,
100 mg twice per day, or 200 mg twice per day. Randomization was
stratified by baseline platelet count (#503 103/mL,.503 103/mL
to #1003 103/mL, and .1003 103/mL) and geographic region
(North America vs Europe vs rest of world). PAC203 was an open-
label study, and therefore treatment assignments were known.
Patients started treatment at their randomly assigned dose. Dose
escalation was not permitted; dose modification guidelines were
provided for treatment-related events, as described in supplemental
Methods. Patients in all arms were treated through week 24 or until
progressive disease (increase in spleen volume $25%, splenic
irradiation, splenectomy, or leukemic transformation), unacceptable
toxicity, or withdrawal from study. Patients who experienced clinical
benefit at 24 weeks had the option of continuing to receive
pacritinib until study completion, at which point they could transition
to an expanded access (individual patient/named patient basis)
program.
Study assessments
Spleen volume (by magnetic resonance imaging or computed
tomography) was reviewed centrally by a blinded, independent
radiology facility at baseline, every 12 weeks on study, and at the
end of treatment. Patient-reported symptoms were recorded once
per day using the MPN-SAF TSS 2.0. TSS was calculated as the
sum of 7 scores (tiredness, satiety, abdominal discomfort, night
sweats, pruritis, bone pain, and left rib pain), in contrast to the 6-
component version (excluding tiredness), which supported the
approval of other JAK inhibitors.12,13 Scores for Patient Global
Impression of Change (PGIC)14 were assessed every 12 weeks
until the end of treatment. Myeloid mutations were assessed using
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an International Organization for Standardization (ISO 15189:
2012)–accredited Illumina TruSeq Custom Amplicon Panel that
assessed 32 genes and reported variants with allele frequency
$1%.15
Safety monitoring included study visits, laboratory assessments,
QTc monitoring (reviewed centrally by an independent cardiologist
blinded to treatment assignment) at baseline and at the end of
weeks 4, 12, and 24 and every 12 weeks on study treatment, as well
as monitoring of left ventricular ejection fraction at the end of weeks
4, 12, and 24 and every 24 weeks on study treatment. Dose
modification guidelines, including those for $2 grade reduction in
platelet counts, grade $2 hemorrhage, and grade $2 cardiac
toxicity, were more stringent than those used in the previous
PERSIST-1 and PERSIST-2 studies. Adverse events were classi-
fied and graded according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events v4.03. Cardiac
and hemorrhagic events were classified by Standardized Medical
Dictionary for Regulatory Activities (MedDRA) Query (SMQ). See
supplemental Methods for additional details.
Population PK and PD modeling
Population PK modeling was conducted to describe pacritinib PK
and to identify intrinsic and extrinsic factors that could potentially
influence pacritinib PK among individuals. Population PK/PD
modeling was conducted to assess the relationship between
pacritinib plasma concentration and change from baseline spleen
volume and TSS score. Population PK modeling was based on all
available data from 16 studies (11 phase 1 and 5 phase 2 or 3
studies), including healthy volunteers and patients with myelofibro-
sis and other hematologic malignancies. Population PK/PD
modeling was based on PERSIST-1, PERSIST-2, and PAC203
trial data and analyzed SVR and TSS reduction as continuous
variables. Associations between exposure and efficacy outcomes
were evaluated on binomial end points (responder or nonresponder
based on $35% SVR or $50% reduction in TSS) using logistic
regression. All modeling work was performed using NONMEM
version 7.3 (ICON Development Solutions, Dublin, Ireland), and
exposure-efficacy evaluations were conducted using R Statistical
Software (version 3.5.3; https://www.R-project.org/). Further
details on modeling are outlined in supplemental Methods.
Statistical analysis
A sample size of 150 patients was selected to ensure adequate
precision to evaluate efficacy and safety. With 50 patients per arm,
if the true incidence rate for a specified safety event is 5%, then the
chance of observing at least 1 event among 50 patients would be
92%. Primary efficacy and safety analyses were performed in
patients who received at least 1 dose of pacritinib. As an exploratory
analysis, SVR and TSS end points were analyzed among patients
who received at least 1 dose of pacritinib and had evaluable
baseline and follow-up assessments relevant for that end point
(evaluable population). The number of patients with $50%
reduction in TSS and those with a $35% reduction in SVR were
summarized using counts and percent. PGIC scores and safety
analyses were summarized by treatment arm using descriptive
statistics. Although no formal hypothesis testing was planned, an ad
hoc Cochran-Armitage trend test was performed to evaluate
efficacy end points.
Results
Patient disposition and exposure
From July 2017 to January 2019, 165 patients were randomly
assigned, and 161 received treatment with pacritinib 100 mg once
per day (n 5 52), 100 mg twice per day (n 5 55), or 200 mg twice
241 patients screened
165 randomized
55 assigned to pacritinib 100mg QD
(52 received pacritinib) 
55 assigned to pacritinib 100mg BID
(55 received pacritinib) 










11 on Expanded Access after study
completion
14 on Expanded Access after study
completion
10 on Expanded Access after study
completion
52 discontinued pacritinib (100%)
     6 due to adverse event (11.5%)
     24 physician decision (46.2%),
     including 17 with protocol-
     defined progressive disease
     11 patient withdrawal (21.2%)
     1 death (1.9%)
     10 study completion (19.2%)
     0 lost to follow-up (0%)  
55 discontinued pacritinib (100%)
     11 due to adverse event (20.0%)
     18 physician decision (32.7%),
     including 10 with protocol-
     defined progressive disease
     7 patient withdrawal (12.7%)
     1 death (1.8%)
     17 study completion (30.9%)
     0 lost to follow-up (0%)
     1 other (stem cell transplant)
     (1.8%)
54 discontinued pacritinib (100%)
     10 due to adverse event (18.5%)
     23 physician decision (42.6%,)
     including 19 with protocol-
     defined progressive disease
     6 patient withdrawal (11.1%)
     0 death (0%)
     13 study completion (24.1%)
     1 lost to follow-up (1.9%)
     1 other (need for prohibited
     medication) (1.9%)  
76 Excluded
     71 ineligible (failed entrance criteria,
     including adverse event in screening)
     5 withdrew consent
Figure 1. Patient disposition. Outcomes for all screened and randomized patients are shown. BID, twice per day; QD, once per day.
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per day (n 5 54; Figure 1). Baseline demographic and disease
characteristics were balanced across arms (Table 1). Median
platelet count was 553 103/mL, and 44.1% of patients (n 5 71)
had a platelet count ,503 103/mL. Hemoglobin was ,10 g/dL in
70.8% of patients (n5 114). Median duration of previous ruxolitinib
exposure was 1.7 years; 76% met study-defined criteria for
ruxolitinib failure, 73% for ruxolitinib intolerance, and 50% for both.
The majority of patients (59%) had $1% peripheral blasts, with
a median of 2.0% peripheral blasts on all arms. Molecular profiling
performed on a subset of patients (n5 110) revealed a mean of 2.5
mutations (range, 1-11 mutations) per patient. High molecular risk
mutations (ASXL1, SRSF2, EZH2, IDH1/2, U2AF1Q157)16 were
detected in 40% of patients, and 7.3% had TP53 mutations
(associated with poor prognosis and leukemic transformation17).
At study completion, 40 patients (24.8%) were still receiving
treatment; 34 of these patients continued therapy off-study under
expanded access. Discontinuation as a result of adverse events
(AEs) was more common at 100 mg twice per day (20.0%) and
200 mg twice per day (18.5%) than at 100 mg once per day
(11.5%). Other reasons for treatment discontinuation included
physician decision (39.1%) and withdrawal by the patient (14.9%).
Table 1. Baseline patient and disease characteristics by treatment arm
Characteristic
Pacritinib
100 mg once per d (n 5 52) 100 mg twice per d (n 5 55) 200 mg twice per d (n 5 54)
Median age (IQR), y 69.5 (64.0-74.0) 69.0 (66.0-73.0) 68.5 (62.0-73.0)
Male sex 31 (59.6) 29 (52.7) 32 (59.3)
Myelofibrosis diagnosis
Primary 28 (53.8) 28 (50.9) 37 (68.5)
Post polycythemia vera 16 (30.8) 18 (32.7) 10 (18.5)
Post essential thrombocythemia 8 (15.4) 9 (16.4) 7 (13.0)
Previous ruxolitinib treatment
Failure 40 (76.9) 41 (74.5) 42 (77.8)
Intolerance 38 (73.1) 41 (74.5) 38 (70.4)
Both 26 (50.0) 28 (50.9) 26 (48.1)
Median duration of previous ruxolitinib treatment (IQR), y 1.7 (0.7-3.0) 1.8 (0.8-3.5) 1.6 (0.4-3.3)
DIPSS risk score*
Intermediate-1 9 (17.3) 14 (25.5) 12 (22.2)
Intermediate-2 25 (48.1) 27 (49.1) 28 (51.9)
High 18 (34.6) 14 (25.5) 14 (25.9)
ECOG PS
0 11 (21.2) 14 (25.5) 17 (31.5)
1 32 (61.5) 29 (52.7) 29 (53.7)
2 9 (17.3) 12 (21.8) 8 (14.8)
Platelet count, 3 103/mL
Median (IQR) 59 (41 -111 ) 53 (33 -116 ) 59 (29 -91 )
,50 23 (44.2) 24 (43.6) 24 (44.4)
Hemoglobin ,10g/dL 35 (67.3) 38 (69.1) 41 (75.9)
RBC transfusion status†
Dependent 15 (28.8) 15 (27.3) 21 (38.9)
Independent 24 (46.2) 23 (41.8) 20 (37.0)
Intermediate 13 (25.0) 16 (29.1) 13 (24.1)
Platelet transfusion dependent‡ 6 (11.5) 5 (9.1) 6 (11.1)
Peripheral blasts $1% 32 (61.5) 30 (54.5) 32 (59.3)
Median peripheral blasts (IQR), % 2.0 (1.0-3.0) 2.0 (0.9-4.0) 2.0 (1.0-2.0)
Median white blood cell (IQR), 3109/L 10.9 (4.9-34.9) 7.8 (3.5-18.6) 7.1 (4.2-12.6)
Median spleen length (IQR), cm 12.0 (9.5-19.5) 15.0 (11.0-20.0) 14.0 (10.0-20.0)
Median spleen volume (IQR), cm3 2434 (1694-3041) 2169 (1651-2839) 2655 (1630-4069)
All data are no. (%) unless otherwise specified.
DIPSS, Dynamic International Prognostic Scoring System; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range.
*High molecular risk as defined by Tefferi et al.16
†RBC transfusion status as defined by Gale criteria.28
‡Platelet transfusion dependence defined by any platelet transfusion required during the past month.
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Protocol-defined progression of disease occurred in all dosing
arms, including splenic progression (100 mg once per day, n5 13;
100 mg twice per day, n 5 10; 200 mg twice per day, n 5 16) and
leukemic transformation (100 mg once per day, n 5 2; 100 mg
twice per day, n5 0; 200 mg twice per day, n5 2, including 1 with
concomitant splenic progression). Patients reached week 24 and
had evaluable efficacy data at similar rates across dosing arms for
SVR (100 mg once per day, 50.0% [26 of 52]; 100 mg twice per
day, 47.3% [26 of 55]; 200 mg twice per day, 50% [27 of 54]) and
TSS (100 mg once per day, 44.2% [23 of 52]; 100 mg twice per
day, 49.1% [27 of 55]; 200 mg twice per day, 44.4% [24 of 54]).
Median duration of pacritinib treatment on study was 23 weeks
(100 mg once per day), 20 weeks (100 mg twice per day), and
21 weeks (200 mg twice per day). Patients treated at 200 mg twice
per day had higher rates of dose interruptions and reductions
(35.2% and 20.4%, respectively) than those at 100 mg twice
per day (20.0% and 9.1%) or 100 mg once per day (19.2% and
0%). Dose intensity (average daily ratio of actual vs planned dose
intensity) was high across arms: 100 mg once per day, 99.1%;
100 mg twice per day, 94.7%; 200 mg twice per day, 90.7%.
SVR
At week 24, the SVR response rate was highest in the 200 mg
twice per day arm (9.3%) compared with lower dose arms (100 mg
once per day, 0%; 100 mg twice per day, 1.8%; Ptrend 5 .012;
Table 2). The median percent reduction in spleen volume was
greatest on the 200 mg twice per day arm (–10.1%; interquartile
range, 223.8% to 2.5%) compared with lower doses (Figure 2A).
Across all arms, baseline cytopenias were common in patients with
an SVR response: 6 of 6 responders had baseline hemoglobin
,10g/dL, and 4 of 6 responders had baseline platelet counts
,503 103/mL. Notably, of the 5 SVR responders at 200 mg twice
per day, 4 had baseline platelet counts ,503 103/mL; thus, the
SVR rate among patients with severe thrombocytopenia was
16.7% (4 of 24). In the evaluable population with spleen volume
data at week 24, the SVR rate at 200 mg twice per day was 18.5%,
and it was 30.8% overall and among patients with severe baseline
thrombocytopenia.
Symptom reduction
At week 24, the TSS response rate was similar across all arms
(100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg
twice per day, 7.4%; Table 2). Among the evaluable population with
TSS data at week 24, the TSS response rate was also similar
across arms (17.4%, 14.8%, 16.7%; Ptrend . .05). Baseline
cytopenias were common among patients with a TSS –50%
response: 8 of 12 responders had hemoglobin ,10 g/dL, and 4 of
12 responders had platelet counts ,503 103/mL. Although
response rates were similar across arms, when analyzed as
a continuous variable, the percent decrease in TSS showed deeper
reductions with escalating doses, with the greatest median
reduction at 200 mg twice per day (–27.3%; interquartile range,
239.2% to 1.2%; Figure 2B). TSS reduction occurred in both
spleen-related symptoms (satiety, abdominal discomfort, and left rib
pain) and cytokine-related symptoms (night sweats, itching, and
bone pain), particularly on the 200 mg twice per day arm (Figure 3).
The subset of TSS responders hardly overlapped with SVR
responders; the proportion of patients who achieved either
response was highest at 200 mg twice per day (14.8%) compared
with 100 mg twice per day (7.3%) or 100 mg once per day (7.7%).
The percentage of patients reporting at least minimal improvement
on the PGIC score at week 24 was greatest in the 200 mg twice
per day arm (33.3% [18 of 54]) compared with 100 mg twice
per day (23.6% [13 of 55]) or 100 mg once per day (19.2% [10 of
52]) doses. Among evaluable patients, more than one third of
patients on all arms reported that their symptoms were much or very
much improved by week 24 (Figure 4).
Changes in hematologic parameters
Platelet counts remained stable for the majority of patients on study,
including those with severe thrombocytopenia at baseline
(Figure 5A), although some patients required dose modifications
or discontinuations because of thrombocytopenia (supplemental
Table 1). Among patients who had received RBC transfusions
within 90 days of enrollment or during screening, the median rate of
RBC transfusions (units per month) was stable or decreasing
through week 24 (Figure 5B), and reductions in transfusion burden
by 50% or greater were observed in all dosing arms: 100 mg once
per day: 17.9% (5 of 28); 100 mg twice per day: 35.5% (11 of 31);
200 mg twice per day: 14.7% (5 of 34). Among patients with
baseline hemoglobin levels#10 g/dL, a larger proportion treated at
200 mg twice per day had hemoglobin increase by $1 g/dL
(100 mg once per day: 2.8% [n 5 1]; 100 mg twice per day: 2.8%
[n 5 1]; 200 mg twice per day: 9.5% [n 5 4]) and by $2 g/dL
(100 mg once per day, 0%; 100 mg twice per day, 0%; 200 mg
twice per day, 4.8% [n 5 2]) in the absence of transfusion in the
Table 2. Summary of spleen volume and symptom reduction from








n/N % n/N % n/N %
SVR rate
Overall 0/52 0 1/55 1.8 5/54 9.3
Evaluable 0/26 0 1/26 3.8 5/27 18.5
Patients with platelet count
,503 103/mL
Overall 0/23 0 0/24 0 4/24 16.7
Evaluable 0/9 0 0/10 0 4/13 30.8
Median percent spleen volume








Overall 4/52 7.7 4/55 7.3 4/54 7.4
Evaluable 4/23 17.4 4/27 14.8 4/24 16.7
Patients with platelet count
,503 103/mL
Overall 2/23 8.7 0/24 0 2/24 8.3
Evaluable 2/9 22.2 0/10 0 2/13 15.4








SVR is defined as $35% reduction; TSS (7-component version) response is defined as
$50% reduction. Response rates are provided for the overall population (all treated
patients) and for the evaluable population (patients with week 24 data).
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8 weeks leading up to week 24. Among patients who were
dependent on RBC transfusions at baseline, a subset of patients in
all arms achieved transfusion independence by week 24: 100 mg
once per day: 13% (2 of 15); 100 mg twice per day: 13% (2 of 15);
200 mg twice per day: 9.5% (2 of 21).
Safety
The most commonly reported treatment-emergent AEs are listed in
Table 3. The majority of common nonhematologic AEs were mild or
moderate in severity, and rates were similar across dosing arms with
the exception of gastrointestinal events, which occurred more
commonly in patients treated at 200 mg twice per day (72.2% [39
of 54]) than at lower doses (100 mg once per day: 50.0% [26 of
52]; 100 mg twice per day: 54.5% [30 of 55]). These events were
largely grade 1 or 2 (81 of 95, or 85.3% of patients with events) and
usually occurred within the first 8 weeks of treatment. Diarrhea was
common but generally manageable with standard antidiarrheal
agents and tended to be short-lived: the median duration of
pacritinib-related diarrhea at 200 mg twice per day was 2 weeks.
Neoplasms were reported in 5 patients (3.1%); all reports were skin
cancers, and no cases of neoplasms were reported at 200 mg
twice per day.
The most common hematologic AEs were thrombocytopenia and
anemia, both of which occurred more frequently in patients treated
at 200 mg twice per day (Table 3). The majority of thrombocyto-
penia and anemia AEs were classified as grade 3 or 4, although it is
important to note that a majority of patients had baseline grade $2
thrombocytopenia (101 of 161, or 62.7% with platelet count
,753 103/mL) and anemia (114 of 161, or 70.8% with
hemoglobin ,10 g/dL), and thus development of higher-grade
AEs required a relatively small decline in platelet counts, which
were already depressed as a consequence of the disease. Dose
modifications as a result of thrombocytopenia occurred in all arms,
although the majority occurred on the 100 mg twice per day and
200 mg twice per day arms; among patients treated at 200 mg
twice per day, 3 patients required dose reductions and 3 required
drug discontinuation because of thrombocytopenia, as shown in
supplemental Table 1.
Severe cardiac events (per SMQ) were uncommon. Grade 1 and 2
events, most commonly peripheral edema and QT prolongation,
were more common at 200 mg twice per day (40.7% [n5 22]) than
at lower doses (100 mg once per day: 21.2% [n 5 11]; 100 mg
twice per day: 21.8% [n 5 12]) (supplemental Table 2). The most
common higher-grade cardiac event was decreased left ventricular
ejection fraction detected on per-protocol cardiac imaging: 2
events were described at each of the lower doses (100 mg once
per day: 3.8% [2 of 52]; 100 mg twice per day: 3.6% [2 of 55]), and
no such event was reported at 200 mg twice per day. There was no
Note: one patient with 302% increase from baseline TSS score represented with truncated bar in order to






















































Figure 2. Spleen volume and TSS reduction in
evaluable patients. Waterfall plots for SVR (A)
and TSS (B) reduction from baseline to week 24.
TSS is the 7-component version of the Total Symp-
tom Score (inclusive of “tiredness”).
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excess in grade 3 or 4 cardiac events at the highest dose (100 mg
once per day: 5.8% [n 5 3]; 100 mg twice per day: 5.5% [n 5 3];
200 mg twice per day: 3.7% [n5 2]; no grade 4 events). The mean
change in QTc interval between baseline and week 24 was110 to
11 msec on all arms; no patient had a QTc .500 msec
(supplemental Table 3; supplemental Figure 1). There was one
grade 5 cardiac event on study, which occurred in a patient
receiving 100 mg twice per day who died of heart failure in the
setting of progressive hyperleukocytosis.
Bleeding events (per SMQ) were more common at 200 mg twice
per day (42.6% [n 5 23]) than at lower doses (100 mg once per
day: 36.5% [n 5 19]; 100 mg twice per day: 25.5% [n 5 14]) but
were largely grade 1 or 2 in severity, with the most common being
epistaxis and bruising (supplemental Table 2). There was no excess
in grade 3 or 4 bleeding events at the highest dose (100 mg once
per day: 7.7% [n5 4]; 100 mg twice per day: 0% [n 5 0]; 200 mg
twice per day: 5.6% [n5 3]; no grade 4 events). The most common
high-grade bleeding event was epistaxis. Two grade 5 bleeding
events occurred, 1 at 100 mg twice per day and 1 at 200 mg twice
per day, both subdural hemorrhages. Although bleeding events of
all grades were more common in patients with baseline platelet
counts ,503 103/mL (100 mg once per day: 60.9% [n 5 14];
100 mg twice per day: 33.3% [n 5 8]; 200 mg twice per day:
75.0% [n 5 18]), the magnitude of between-arm differences in
bleeding rates in this subgroup was similar to that of the population
as a whole.
The rate of fatal events was similar across all arms: 100 mg once
per day: 7.7% (n 5 4; sepsis, disease progression, tuberculosis,
and general state deterioration); 100 mg twice per day: 5.5%
(n 5 3; disease progression, subdural hemorrhage, and heart failure);



















































Figure 3. Change in individual symptom scores per MPN-SAF TSS 2.0 between baseline and week 24 by dosing arm. Median percent change in individual
symptom scores show greatest improvement on the 200 mg twice per day dose for the majority of abdominal- and cytokine-related symptoms. Abd, abdominal; MPN-SAF TSS,























Figure 4. PGIC assessment (evaluable population) at week
24 by dosing arm. Number of patients with any improvement in
disease symptoms was greatest at 200 mg twice per day (n 5 18)
compared with lower doses (100 mg once per day, n 5 10; 100 mg
twice per day, n 5 13).
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Population PK and PD modeling
Population PKs for pacritinib were established on the basis of
pooled data from 16 studies that included 630 patients who
received pacritinib at daily doses of 100 to 600 mg (supplemental
Methods). Pacritinib population PKs were characterized by a 2-
compartment disposition model with first-order absorption and
elimination. Both absorption and bioavailability were influenced by
the amount of drug administered. Systemic exposure (area under
the concentration-time curve, maximum concentration, and mini-
mum concentration) for the 100 mg once per day and 100 mg twice
per day regimens was generally lower than that achieved with
higher doses (200 mg twice per day and 400 mg once per day),
although there was overlap (supplemental Table 4). Simulations
indicate that pacritinib concentrations are expected to reach steady
state within a week. Accumulation of drug after multiple doses
seems to be low. Patient factors (age, sex, performance status,
platelet count, hemoglobin, and hepatic function) were not
significantly associated with pacritinib concentrations.
The population PK/PD modeling for pacritinib includes 2-
compartment, first-order absorption and elimination with dose-
dependent absorption and bioavailability. Population PK/PD mod-
eling based on data from PAC203 and both of the phase 3
PERSIST studies showed that higher pacritinib doses were
associated with greater SVR (n 5 280) and TSS reduction (n 5
282) (Figure 6). Exposure-response analysis showed that higher
systemic pacritinib levels were significantly associated with higher
SVR rates (based on quartiles for area under the time-concentration
curve and minimum concentration in 182 patients; P , .05).
Although there was a trend toward high TSS response rate with
higher exposure to pacritinib, this was not statistically significant
(n 5 162, P , .1; supplemental Figure 2).
Discussion
Data from PAC203 and from dose- and exposure-response
modeling demonstrate that pacritinib 200 mg twice per day
provides greater efficacy compared with lower doses and has
a manageable safety profile. The PAC203 study was conducted in
a population with advanced myelofibrosis and prolonged previous
exposure to ruxolitinib. A substantial number of patients had high-
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Figure 5. Changes in hematologic parameters. (A) Median percent change in platelet counts on study treatment by dosing arm. (B) Median number of RBC transfusions
per month among patients who received RBC transfusions before study treatment by dosing arm.
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mutations than has been reported in other myelofibrosis cohorts,
including those with previous ruxolitinib exposure (7.3% on
PAC203 vs 1% to 4% previously reported18-21). The majority of
patients were anemic and thrombocytopenic, a profile character-
istic of the myelodepletive myelofibrosis phenotype.22 The use of
current first-line therapies for myelofibrosis, such as ruxolitinib and
fedratinib, is limited in myelodepletive disease because these drugs
can exacerbate cytopenias. Myelofibrosis patients with baseline
platelet counts,503 103/mL were excluded from pivotal trials that
led to approval of other JAK inhibitors,13,23 and studies of ruxolitinib
in thrombocytopenic patients have focused exclusively on those with
baseline platelet counts of 503 103/mL and above.24,25 In contrast,
pacritinib has demonstrated clinical benefit across groups of myelofi-
brosis patients in multiple clinical studies,1,2 and most myelofibrosis
patients with severe thrombocytopenia are able to tolerate pacritinib at
200 mg twice per day without requiring dose reductions or holds.
As observed in PERSIST-1 and PERSIST-2, patients with severe
thrombocytopenia treated on PAC203 attained spleen and
symptom responses despite previous exposure to ruxolitinib.
Although the biologic basis of this well-documented observation
is not fully understood, it is likely a function of both the kinase
inhibition profile of pacritinib, which includes IRAK1, and differences
in myelofibrosis biology in which thrombocytopenia and associated
low JAK2 allele burden may represent a distinct myelofibrosis
subgroup that is particularly responsive to pacritinib.26 The
correlation between disease genotype and response to pacritinib
therapy will be a correlative of interest in ongoing studies.
Pacritinib was generally well tolerated across all dose levels on
PAC203, with manageable toxicities because of appropriate patient
selection and the use of dose modification guidelines. Although the
200 mg twice per day dose was associated with higher rates of
AEs, there was no excess in high-grade cardiac or hemorrhagic
events compared with lower doses, and AE rates were lower than
previously observed on the 200 mg twice per day arm of PERSIST-
2. In fact, bleeding rates at 200 mg twice per day (42.6%) were
comparable to those observed in ruxolitinib-treated patients
enrolled in the COMFORT studies (32.6%)27, which excluded
patients with platelet counts ,1003 103/mL. These comparisons
suggest that the PAC203 risk minimization measures were
effective.
A limitation of the PAC203 study is that the dose modification
guidelines required an open-label study. Although lack of blinding
should have little impact on the evaluation of SVR and key safety
measures, it is possible that patient-reported outcomes could be
biased by knowledge of treatment assignment.
The results of this phase 2 study informed the dose selection for an
ongoing phase 3 randomized study (PACIFICA) comparing
pacritinib 200 mg twice per day with physician’s choice therapy
(including low-dose ruxolitinib) for patients with myelofibrosis and
severe thrombocytopenia (NCT03165734). PACIFICA will include
the risk mitigation measures implemented in the PAC203 study.
There is a lack of available treatment options for patients with severe
thrombocytopenia, including those who are intolerant of or resistant
to ruxolitinib. Pacritinib remains the only prospectively evaluated
Table 3. Summary of most common treatment-emergent AEs
Pacritinib, no. (%)
100 mg once per d (n 5 52) 100 mg twice per d (n 5 55) 200 mg twice per d (n 5 54)
Any grade Grade 3 to 4 Any grade Grade 3 to 4 Any grade Grade 3 to 4
Nonhematologic AEs
Diarrhea 10 (19.2) 1 (1.9) 12 (21.8) 2 (3.6) 16 (29.6) 3 (5.6)
Nausea 12 (23.1) 0 11 (20.0) 0 15 (27.8) 0
Fatigue 9 (17.3) 3 (5.8) 13 (23.6) 2 (3.6) 13 (24.1) 2 (3.7)
Abdominal pain 9 (17.3) 0 6 (10.9) 2 (3.6) 13 (24.1) 3 (5.6)
Fever 8 (15.4) 1 (1.9) 9 (16.4) 1 (1.8) 7 (13.0) 1 (1.9)
Peripheral edema 7 (13.5) 0 5 (9.1) 0 9 (16.7) 1 (1.9)
Decreased appetite 6 (11.5) 0 4 (7.3) 0 10 (18.5) 1 (1.9)
Pruritis 2 (3.8) 0 10 (18.2) 1 (1.8) 6 (11.1) 0
Constipation 2 (3.8) 0 1 (1.8) 0 10 (18.5) 0
Pneumonia 4 (7.7) 2 (3.8) 2 (3.6) 2 (3.6) 5 (9.3) 5 (9.3)
Hyperuricemia 1 (1.9) 1 (1.9) 2 (3.6) 1 (1.8) 3 (5.6) 3 (5.6)
Hyponatremia 0 0 3 (5.5) 3 (5.5) 3 (5.6) 2 (3.7)
Dehydration 0 0 3 (5.5) 3 (5.5) 4 (7.4) 1 (1.9)
Hypertension 0 0 3 (5.5) 3 (5.5) 2 (3.7) 1 (1.9)
Hematologic AEs
Thrombocytopenia* 11 (21.2) 10 (19.2) 12 (21.8) 12 (21.8) 22 (40.7) 18 (33.3)
Anemia 5 (9.6) 5 (9.6) 6 (10.9) 4 (7.3) 13 (24.1) 11 (20.4)
Neutropenia† 3 (5.8) 3 (5.8) 3 (5.5) 3 (5.5) 3 (5.6) 3 (5.6)
All events are reported regardless of relatedness and are those occurring as any grade in $15% or as grade 3 to 4 in $5% of patients in any arm.
*Includes platelet count decrease.
†Includes neutrophil count decrease.
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therapy supported by clinical data for treating patients with
myelofibrosis and severe thrombocytopenia, an area of unmet need
and the focus of the current phase 3 trial.
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Figure 6. Dose-response modeling. Modeling based
on efficacy data from previous phase 3 (PERSIST-1 and
PERSIST-2) studies as well as the PAC203 phase 2
study. Increasing doses are associated with better
responses for both spleen volume and symptom score
reduction.
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